Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Agios Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 09:40PM GMT
Release Date Price: €43.21 (+1.65%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon, everyone. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs.

And we're pleased to have the Agios team here with us. So we have Jackie Fouse, CEO; and Andrew Hirsch, CFO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Maybe to start here, you could walk us through the long-term strategy for Agios. You've got 2 commercial drugs. You've got label expansions on TAP and a pretty broad research pipeline. So looking forward, how do you continue executing in a focused manner while you expand the pipeline here with these opportunities?

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Yes. Salveen, I guess the first thing I would say is you come into a terrific company, position of strength, you just don't want to mess it up, right? So I think that's one thing. But we're going to continue to -- the Agios' tradition of following the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot